ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / PYXS / insiders
KROS (66) SLGL (54) SIGA (72) BBOT (37) ⌘ Pro Terminal β†’

Pyxis Oncology Inc. (PYXS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.81 -4.23% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.79

Pyxis Oncology Inc. (PYXS) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (29/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE E β€’ RED ALERT Cap $226.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PYXS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is PYXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Pyxis Oncology Inc. (NASDAQ: PYXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.81 (-4.23% 1D, market cap $226.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PYXS ranks #880 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does PYXS compare to KROS and SLGL in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PYXS carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 82.8%, and ROIC of -35.0%. By comparison, KROS (Keros Therapeutics Inc.) holds a C+ grade (66/100 RQD, P/E N/A, ROIC 85.0%, cap $225.2M) and SLGL (Sol-Gel Technologies Ltd.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -35.0%, cap $224.8M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PYXS?
β–Ό

Per PYXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782223), Pyxis Oncology Inc. generated $13.9M in revenue (-14.2% YoY), -$79.6M in net income, and -$63.5M in free cash flow against $91.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.79 (-0.95%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (29/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D-
Cash (6)Whales (4)SEC (8)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.3% Base Target
$6 Bull$2 Base$1 Bear
πŸ“¬ FREE PYXS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for PYXS)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
πŸ” WHY PYXS SCORES 29/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–² #2 Bullish Driver: Macro Regime Fit+8/20 pts (28% of score)

FRED Regime Γ— Technicals: 17% of 52W Range β€’ RSI-14 at 34.8 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
37
Grade E$2.01-12.4% Next Q
Q2 (-2Q)
34
Grade E$1.76-4% Next Q
Q3 (-1Q)
32
Grade E$1.69+7.1% Next Q
Current
29
Grade E$1.81-9.8% Hist 90D Ξ±
Trajectory: E (37) β†’ E (29)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a PYXS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While PYXS currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.63) and Max Pain ($1.90) forces dealer call-delta covering toward $5.83.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PYXSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPYXS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

PYXS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PYXS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PYXS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PYXS)

  • βœ“Walkthrough of PYXS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
PYXS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.84%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-02O $1.83H $1.86L $1.68C $1.81VOL 427.9K
RES: $4.99SUP: $1.60SMA50: $2.63SMA200: $2.16
$4.33$3.58$2.82$2.06$1.31RES $4.99SUP $1.60$1.812026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PYXS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ PYXS Butterfly Map β†’ + Track PYXS β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -14.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PYXS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for PYXS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PYXS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PYXS)

Health Care Rank #880 of 1016 βš”οΈ KROS vs PYXS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (PYXS vs. KROS, SLGL, SIGA, BBOT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pyxis Oncology Inc. (PYXS) ranks #880 by composite RQD confidence (29/100, grade E) and #560 by equity capitalization ($226.0M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and β€” gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with PYXS at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PYXS ACTIVE
Pyxis Oncology Inc.
E 29/100 β€” 82.8% -35.0% -4.23% $226.0M Benchmark Subject
KROS
Keros Therapeutics Inc.
C+ 66/100 β€” β€” 85.0% -2.82% $225.2M /kros-vs-pyxs β†’
SLGL
Sol-Gel Technologies Ltd.
D+ 54/100 β€” β€” -35.0% -0.45% $224.8M /slgl-vs-pyxs β†’
SIGA
SIGA Technologies Inc.
B 72/100 9.8x 68.6% 42.7% -4.40% $228.5M /siga-vs-pyxs β†’
BBOT
BridgeBio Oncology Therapeutics Inc.
D- 37/100 β€” β€” -35.0% -2.96% $216.5M /bbot-vs-pyxs β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001782223

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pyxis Oncology Inc. (PYXS) reported GAAP revenue of $13.9M (-14.2% vs. FY2024 revenue of $16.1M ) , GAAP net income of -$79.6M, operating cash flow of -$63.5M, and free cash flow of -$63.5M (-9.7% YoY). On the balance sheet, PYXS closed FY2025 with $91.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $13.9M -$79.6M -$63.5M -$63.5M $91.5M β€”
FY2024 (FY) 2024-12-31 $16.1M -$77.3M -$57.7M -$57.9M $157.2M β€”
FY2023 (FY) 2023-12-31 $0 -$73.8M -$70.7M -$70.7M β€” β€”

3. PYXS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PYXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Pyxis Oncology Inc. (NASDAQ: PYXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.81 (-4.23% 1D, market cap $226.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PYXS ranks #880 in composite RQD confidence.

How does PYXS compare to KROS and SLGL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PYXS carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 82.8%, and ROIC of -35.0%. By comparison, KROS (Keros Therapeutics Inc.) holds a C+ grade (66/100 RQD, P/E N/A, ROIC 85.0%, cap $225.2M) and SLGL (Sol-Gel Technologies Ltd.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -35.0%, cap $224.8M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PYXS?

Per PYXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782223), Pyxis Oncology Inc. generated $13.9M in revenue (-14.2% YoY), -$79.6M in net income, and -$63.5M in free cash flow against $91.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PYXS trading relative to its 50-day, 200-day, and 52-week technical levels?

PYXS last traded at $1.81 (-4.23% on volume of 686,540 shares), positioning the stock -31.18% below its 50-day simple moving average ($2.63) and -16.20% below its 200-day simple moving average ($2.16). Across its 52-week range of $1.03 to $5.55, PYXS sits at the 17.3% percentile with a 14-day RSI of 34.8 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.58 to $2.04).

PYXS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Are PYXS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies PYXS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: PYXS RQD Cockpit PYXS 12M Forecast PYXS Earnings & Move PYXS Dividends & DRIP PYXS Insiders & 13F PYXS Whale Options PYXS Profit Sankey PYXS News & Why
ROARABLE RATING BRIEF β€’ RQD 29/100 (E) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

PYXS β€” Pyxis Oncology Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:40:35Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PYXS scores 29 out of 100 with a letter grade of E, labeled "Roarable Strong Sell β€” Forensic Risk / Avoid." The five pillars break down as follows. Fundamental cash engine scores 6/20, reflecting ROIC of -35% and an FCF yield of 0%. Whale 13F flow scores 4/20, covering institutional accumulation and options positioning. Insider conviction scores 3/20, based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 8/20, with a beta of 1.0 and sector sensitivity noted. Forensic balance sheet scores 8/20, citing an Altman Z of 2.5, a Piotroski F of 3/9, and a Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the rating points to weak cash generation and low scores across ownership-signal pillars. The fundamental pillar is the most direct caution: negative ROIC and zero FCF yield indicate the business is not currently converting capital into owner cash returns. The insider and whale pillars score lowest, which the rating reads as limited conviction from insiders and institutions in the source data. The balance-sheet pillar is middling rather than distressed, so solvency is a less acute concern than operating losses. Upside drivers, if any, would have to come from changes in the cash engine or in ownership conviction, neither of which the rating currently shows. Valuation cannot be assessed on earnings multiples because P/E and EV/EBITDA are not available in source data.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$13.9M$-84.4M$-79.6MN/A$-63.5M$15.4MN/A
FY 2024$16.1M$-89.5M$-77.3MN/A$-57.9M$19.5MN/A
FY 2023$0.0M$-82.2M$-73.8MN/A$-70.7MN/AN/A

Per the SEC financials, operating losses and negative free cash flow appear in each reported period, and revenue declined from $16.1M in FY 2024 to $13.9M in FY 2025. Per the market data, ROIC is -35% and the operating margin is -60%. The Roarable RQD rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity of 0.5. Cash is reported for FY 2025 and FY 2024, and debt is not available in source data for any period.

Recent Catalysts & News Wire Analysis

The news feed contains six items, all tagged to PYXS, from sources including Yahoo! Finance Canada, Seeking Alpha, StockInvest.us, TradingView, Stock Titan, and ad-hoc-news.de. Headlines cover general market and institutional coverage, a Seeking Alpha piece titled around a better runway for remaining R&D, a Stock Titan item on a cancer drug spanning three presentations, and an ad-hoc-news.de item referencing a Wells Fargo price target of USD 19.00. The Seeking Alpha item is classified as a CATALYST and carries a GREEN light; the remaining items are classified as market wire and carry YELLOW lights. The Wells Fargo target is listed in the headline but is not corroborated by the analyst section. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so there are no graph-derived catalysts.

Open Questions

  • What are the company's products, pipeline stage, and revenue sources, given that the profile and business description lack detail?
  • What explains the decline in revenue from FY 2024 to FY 2025, and what is driving the operating losses?
  • Why is debt reported as N/A across all periods while the RQD rating cites a Debt/Equity of 0.5?
  • What is the cash runway implied by $15.4M in cash against FY 2025 negative FCF of $-63.5M?
  • What is the basis for the Wells Fargo USD 19.00 target referenced in the news feed, given that analyst data is absent?

PYXS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pyxis Oncology Inc. (PYXS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to PYXS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PYXS Bull vs. Bear Conversation Board β€” What's Your Call at $1.81?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PYXS 🐻 67% BEARISH CONVICTION
1. Pick Your Side on PYXS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.66 (-12.2%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is PYXS (E β€’ RQD 29/100) a Buy at $1.89?

Welcome to the PYXS (Pyxis Oncology Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell β€” Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.42 (-24.9%)
Spot @ $1.89

Pump the brakes on PYXS β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PYXS, but look at what you are paying: current EV/EBITDA multiples with 82.8% gross margins. Unless Pyxis Oncology Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $2.32 (+22.8%)
Spot @ $1.89

PYXS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PYXS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.89 (52-wk range $1.77 - $2.18), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%